Deals
Raptor Soars After Retrophin Is Said to Consider Bid
- Drugmaker also has attracted interest from other companies
- No agreement has been reached, firms could decide against deal
This article is for subscribers only.
Raptor Pharmaceutical Corp. jumped in early trading Thursday after Retrophin Inc., the pharmaceutical company founded by controversial entrepreneur Martin Shkreli, was said to be considering an acquisition of the company.
Retrophin is considering the deal to boost growth in treatments for rare diseases, according to people familiar with the matter. Raptor shares rose 12 percent to $7.72 at 9:34 a.m., after earlier rising as much as 16 percent for their biggest gain since April. Retrophin fell less than 1 percent to $17.16.